HQ Function

Served as the central corporate office, directing global operations, research and development strategy, commercial activities, and administrative functions prior to its acquisition by Ionis Pharmaceuticals.

Notable Features:

Located in Boston's dynamic Seaport District, known for its modern infrastructure and concentration of life science companies. The office likely featured contemporary design facilitating collaboration and innovation.

Work Culture:

As a company dedicated to rare diseases, Akcea likely cultivated a mission-driven, scientifically rigorous, and patient-focused work environment. The culture would have emphasized innovation, collaboration, and agility in addressing unmet medical needs. Post-acquisition, employees were integrated into Ionis Pharmaceuticals.

HQ Significance:

The Boston headquarters provided Akcea with strategic access to a rich ecosystem of talent, leading academic and medical institutions, research collaborators, and venture capital, crucial for a developing biotech.

Values Reflected in HQ: The choice of a state-of-the-art facility in a leading biotech innovation hub likely mirrored Akcea's commitment to cutting-edge science, growth, and leadership in developing therapies for rare diseases.

Location:

Prior to its full acquisition by Ionis Pharmaceuticals, Akcea Therapeutics had established a significant global presence. This encompassed clinical trial operations across North America, Europe, and other regions, as well as commercial infrastructure in key markets where its therapies (Tegsedi® and Waylivra®) received regulatory approval. Functions supported globally included clinical development, medical affairs, regulatory submissions and compliance, drug safety, and commercial sales and marketing operations, particularly focused on North America and Europe.

Street Address:

22 Boston Wharf Road, 9th Floor

City:

Boston

State/Province:

MA

Country:

USA